lucentis billing codes - genentech...drug: hcpcs j2778 injection, ranibizumab, 0.1 mg (bill 5 units)...

37
1 of 2 for ® (ranibizumab injection) For additional safety information, please see LUCENTIS full prescribing information. Myopic Choroidal Neovascularization (mCNV) TYPE CODE DESCRIPTION Diagnosis: ICD-10-CM H44.2A1 Degenerative myopia with choroidal neovascularization, right eye H44.2A2 Degenerative myopia with choroidal neovascularization, left eye H44.2A3 Degenerative myopia with choroidal neovascularization, bilateral eye Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference. 10-digit 11-digit 50242-080-02 50242-0080-02 LUCENTIS 0.5-mg vial 50242-080-03 50242-0080-03 LUCENTIS 0.5-mg prefilled syringe Administration procedures: CPT 67028 Intravitreal injection of a pharmacologic agent (separate procedure) CPT modifier –LT Left eye modifier –RT Right eye modifier CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right. SAMPLE CODING These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item. Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer. INDICATIONS & IMPORTANT SAFETY INFORMATION Indications LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with: • Neovascular (wet) age-related macular degeneration (wAMD) • Macular edema following retinal vein occlusion (RVO) • Diabetic macular edema (DME) • Diabetic retinopathy (DR) • Myopic choroidal neovascularization (mCNV) Important Safety Information LUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Upload: others

Post on 07-Jul-2020

5 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

1 of 2

for ® (ranibizumab injection)

For additional safety information, please see LUCENTIS full prescribing information.

Myopic Choroidal Neovascularization (mCNV)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

H44.2A1 Degenerative myopia with choroidal neovascularization, right eye

H44.2A2 Degenerative myopia with choroidal neovascularization, left eye

H44.2A3 Degenerative myopia with choroidal neovascularization, bilateral eye

Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units)

Drug: NDC

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

10-digit 11-digit

50242-080-02 50242-0080-02 LUCENTIS 0.5-mg vial

50242-080-03 50242-0080-03 LUCENTIS 0.5-mg prefilled syringe

Administration procedures: CPT

67028 Intravitreal injection of a pharmacologic agent (separate procedure)

CPT modifier–LT Left eye modifier

–RT Right eye modifier

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

SAMPLE CODING

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

INDICATIONS & IMPORTANT SAFETY INFORMATION IndicationsLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

• Neovascular (wet) age-related macular degeneration (wAMD)

• Macular edema following retinal vein occlusion (RVO)

• Diabetic macular edema (DME)

• Diabetic retinopathy (DR)

• Myopic choroidal neovascularization (mCNV)

Important Safety InformationLUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Page 2: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

2 of 2

LUCENTIS®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2019 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00001082(v1.0) 10/19

Important Safety Information (cont)

WARNINGS AND PRECAUTIONSIntravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.

for ® (ranibizumab injection)

Page 3: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

1 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.311 Diabetes due to underlying condition with unspecified diabetic retinopathy with macular edema

E08.3211Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye

E08.3212 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye

E08.3213 Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E08.3219Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3311Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E08.3312Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E08.3313Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E08.3319Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3411Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye

E08.3412Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye

E08.3413 Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral

SAMPLE CODING

for ® (ranibizumab injection)

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 4: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

2 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.3419Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3511 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye

E08.3512 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye

E08.3513 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral

E08.3519 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye

E08.37X1 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, right eye

E08.37X2 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, left eye

E08.37X3 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, bilateral

E08.37X9 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, unspecified eye

E09.311 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema

E09.3211 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E09.3212 Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E09.3213Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3219Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3311 Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 5: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

3 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.3312Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E09.3313Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3319Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3411Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E09.3412Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E09.3413Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3419Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3511 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E09.3512 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E09.3513 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E09.3519 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E09.37X1 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye

E09.37X2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye

E09.37X3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 6: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

4 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.37X9 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye

E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema

E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3219 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3319 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3419 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 7: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

5 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E10.3519 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E10.37X1 Type 1 diabetes mellitus with macular edema, resolved following treatment, right eye

E10.37X2 Type 1 diabetes mellitus with macular edema, resolved following treatment, left eye

E10.37X3 Type 1 diabetes mellitus with macular edema, resolved following treatment, bilateral

E10.37X9 Type 1 diabetes mellitus with macular edema, resolved following treatment, unspecified eye

E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema

E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E11.3219 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E11.3319 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 8: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

6 of 9For additional safety information, please see LUCENTIS full prescribing information.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E11.3419 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E11.3519 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E11.37X1 Type 2 diabetes mellitus with macular edema, resolved following treatment, right eye

E11.37X2 Type 2 diabetes mellitus with macular edema, resolved following treatment, left eye

E11.37X3 Type 2 diabetes mellitus with macular edema, resolved following treatment, bilateral

E11.37X9 Type 2 diabetes mellitus with macular edema, resolved following treatment, unspecified eye

E13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema

E13.3211 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E13.3212 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E13.3213 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3219 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3311Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E13.3312Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 9: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E13.3313 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3319 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3411 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E13.3412 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E13.3413 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3419 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3511 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E13.3512 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E13.3513 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E13.3519 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E13.37X1 Other specified diabetes mellitus with macular edema, resolved following treatment, right eye

E13.37X2 Other specified diabetes mellitus with macular edema, resolved following treatment, left eye

E13.37X3 Other specified diabetes mellitus with macular edema, resolved following treatment, bilateral

E13.37X9 Other specified diabetes mellitus with macular edema, resolved following treatment, unspecified eye

Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 3 units)

7 of 9For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 10: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

8 of 9For additional safety information, please see LUCENTIS full prescribing information.

INDICATIONS & IMPORTANT SAFETY INFORMATION IndicationsLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

• Neovascular (wet) age-related macular degeneration (wAMD)

• Macular edema following retinal vein occlusion (RVO)

• Diabetic macular edema (DME)

• Diabetic retinopathy (DR)

• Myopic choroidal neovascularization (mCNV)

Important Safety InformationLUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONS Intravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

Diabetic Macular Edema (DME) (cont)

TYPE CODE DESCRIPTION

Drug: NDC

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

10-digit 11-digit

50242-082-02 50242-0082-02 LUCENTIS 0.3-mg vial

50242-082-03 50242-0082-03 LUCENTIS 0.3-mg prefilled syringe

Administration procedures: CPT

67028 Intravitreal injection of a pharmacologic agent (separate procedure)

CPT modifier–LT Left eye modifier

–RT Right eye modifier

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 11: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

9 of 9

LUCENTIS®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2019 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00001082(v1.0) 10/19

Important Safety Information (cont)

WARNINGS AND PRECAUTIONS (cont)In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.

for ® (ranibizumab injection)

Page 12: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

1 of 3For additional safety information, please see LUCENTIS full prescribing information.

Macular Edema Following Retinal Vein Occlusion (RVO)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

H34.8110 Central retinal vein occlusion, right eye, with macular edema

H34.8111 Central retinal vein occlusion, right eye, with retinal revascularization

H34.8112 Central retinal vein occlusion, right eye, stable

H34.8120 Central retinal vein occlusion, left eye, with macular edema

H34.8121 Central retinal vein occlusion, left eye, with retinal revascularization

H34.8122 Central retinal vein occlusion, left eye, stable

H34.8130 Central retinal vein occlusion, bilateral, with macular edema

H34.8131 Central retinal vein occlusion, bilateral, with retinal revascularization

H34.8132 Central retinal vein occlusion, bilateral, stable

H34.8190 Central retinal vein occlusion, unspecified eye, with macular edema

H34.8191 Central retinal vein occlusion, unspecified eye, with retinal revascularization

H34.8192 Central retinal vein occlusion, unspecified eye, stable

H34.8310 Tributary (branch) retinal vein occlusion, right eye, with macular edema

H34.8311 Tributary (branch) retinal vein occlusion, right eye, with retinal revascularization

H34.8312 Tributary (branch) retinal vein occlusion, right eye, stable

H34.8320 Tributary (branch) retinal vein occlusion, left eye, with macular edema

H34.8321 Tributary (branch) retinal vein occlusion, left eye, with retinal revascularization

SAMPLE CODING

for ® (ranibizumab injection)

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 13: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

Macular Edema Following Retinal Vein Occlusion (RVO) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

H34.8322 Tributary (branch) retinal vein occlusion, left eye, stable

H34.8330 Tributary (branch) retinal vein occlusion, bilateral, with macular edema

H34.8331 Tributary (branch) retinal vein occlusion, bilateral, with retinal revascularization

H34.8332 Tributary (branch) retinal vein occlusion, bilateral, stable

H34.8390 Tributary (branch) retinal vein occlusion, unspecified eye, with macular edema

H34.8391 Tributary (branch) retinal vein occlusion, unspecified eye, with retinal revascularization

H34.8392 Tributary (branch) retinal vein occlusion, unspecified eye, stable

Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units)

Drug: NDC

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

10-digit 11-digit

50242-080-02 50242-0080-02 LUCENTIS 0.5-mg vial

50242-080-03 50242-0080-03 LUCENTIS 0.5-mg prefilled syringe

Administration procedures: CPT

67028 Intravitreal injection of a pharmacologic agent (separate procedure)

CPT modifier–LT Left eye modifier

–RT Right eye modifier

2 of 3For additional safety information, please see LUCENTIS full prescribing information.

INDICATIONS & IMPORTANT SAFETY INFORMATION IndicationsLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

• Neovascular (wet) age-related macular degeneration (wAMD)

• Macular edema following retinal vein occlusion (RVO)

• Diabetic macular edema (DME)

• Diabetic retinopathy (DR)

• Myopic choroidal neovascularization (mCNV)

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 14: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

3 of 3

LUCENTIS®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2019 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00001082(v1.0) 10/19

For additional safety information, please see LUCENTIS full prescribing information.

for ® (ranibizumab injection)

Important Safety InformationLUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONSIntravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Page 15: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

1 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR])

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.311 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema

E08.319 Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema

E08.3211Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye

E08.3212Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye

E08.3213Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E08.3219Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3291Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye

E08.3292Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye

E08.3293Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral

E08.3299Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye

E08.3311Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E08.3312Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye

SAMPLE CODING

for ® (ranibizumab injection)

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 16: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

2 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.3313Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E08.3319Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3391Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye

E08.3392Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye

E08.3393Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral

E08.3399Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye

E08.3411Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye

E08.3412Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye

E08.3413Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E08.3419Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E08.3491Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye

E08.3492Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 17: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

3 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.3493Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral

E08.3499Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye

E08.3511 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye

E08.3512 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye

E08.3513 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral

E08.3519 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye

E08.3521Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye

E08.3522Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye

E08.3523Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

E08.3529Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

E08.3531Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye

E08.3532Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

E08.3533Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 18: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

4 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.3539Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye

E08.3541Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

E08.3542Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

E08.3543Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

E08.3549Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye

E08.3551 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye

E08.3552 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye

E08.3553 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral

E08.3559 Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye

E08.3591 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye

E08.3592 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye

E08.3593 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral

E08.3599 Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye

E08.37X1 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, right eye

E08.37X2 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 19: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

5 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E08.37X3 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, bilateral

E08.37X9 Diabetes mellitus due to underlying condition with macular edema resolved following treatment, unspecified eye

E09.311 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema

E09.319 Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema

E09.3211Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E09.3212Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E09.3213Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3219Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3291Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye

E09.3292Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye

E09.3293Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral

E09.3299Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye

E09.3311Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 20: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

6 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.3312Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E09.3313Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3319Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3391Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye

E09.3392Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye

E09.3393Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral

E09.3399Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye

E09.3411Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E09.3412Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E09.3413Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E09.3419Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E09.3491Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 21: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

7 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.3492Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye

E09.3493Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral

E09.3499Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye

E09.3511 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E09.3512 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E09.3513 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E09.3519 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E09.3521Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye

E09.3522Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye

E09.3523Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

E09.3529Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

E09.3531Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye

E09.3532Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 22: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

8 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.3533Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

E09.3539Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye

E09.3541Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

E09.3542Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

E09.3543Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

E09.3549Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye

E09.3551 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye

E09.3552 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye

E09.3553 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

E09.3559 Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye

E09.3591 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye

E09.3592 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

E09.3593 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral

E09.3599 Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye

E09.37x1 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 23: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

9 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E09.37x2 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye

E09.37x3 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral

E09.37x9 Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye

E10.311 Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema

E10.319 Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema

E10.3211 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E10.3212 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E10.3213 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3219 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E10.3291 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye

E10.3292 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye

E10.3293 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral

E10.3299 Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye

E10.3311 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E10.3312 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E10.3313 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3319 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 24: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

10 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E10.3391 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye

E10.3392 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye

E10.3393 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral

E10.3399 Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye

E10.3411 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E10.3412 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E10.3413 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E10.3419 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E10.3491 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

E10.3492 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye

E10.3493 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral

E10.3499 Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye

E10.3511 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E10.3512 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E10.3513 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E10.3519 Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E10.3521 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 25: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

11 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E10.3522 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye

E10.3523 Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

E10.3529Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

E10.3531Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye

E10.3532Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

E10.3533Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

E10.3539Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye

E10.3541Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

E10.3542Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

E10.3543Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

E10.3549Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye

E10.3551 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye

E10.3552 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye

E10.3553 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 26: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

12 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E10.3559 Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye

E10.3591 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye

E10.3592 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

E10.3593 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral

E10.3599 Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye

E10.37X1 Type 1 diabetes mellitus with macular edema resolved following treatment, right eye

E10.37X2 Type 1 diabetes mellitus with macular edema resolved following treatment, left eye

E10.37X3 Type 1 diabetes mellitus with macular edema resolved following treatment, bilateral

E10.37X9 Type 1 diabetes mellitus with macular edema resolved following treatment, unspecified eye

E11.311 Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema

E11.319 Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema

E11.3211 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E11.3212 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E11.3213 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E11.3219 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3291 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye

E11.3292 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 27: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

13 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E11.3293 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral

E11.3299 Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye

E11.3311 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E11.3312 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E11.3313 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E11.3319 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3391 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye

E11.3392 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye

E11.3393 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral

E11.3399 Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye

E11.3411 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E11.3412 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E11.3413 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E11.3419 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E11.3491 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

E11.3492 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye

E11.3493 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 28: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

14 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E11.3499 Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye

E11.3511 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E11.3512 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E11.3513 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E11.3519 Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E11.3521 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye

E11.3522 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye

E11.3523 Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

E11.3529Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

E11.3531Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye

E11.3532Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

E11.3533Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

E11.3539Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye

E11.3541Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

E11.3542Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 29: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

15 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E11.3543Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

E11.3549Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye

E11.3551 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye

E11.3552 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye

E11.3553 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

E11.3559 Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye

E11.3591 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye

E11.3592 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

E11.3593 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral

E11.3599 Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye

E11.37X1 Type 2 diabetes mellitus with macular edema resolved following treatment, right eye

E11.37X2 Type 2 diabetes mellitus with macular edema resolved following treatment, left eye

E11.37X3 Type 2 diabetes mellitus with macular edema resolved following treatment, bilateral

E11.37X9 Type 2 diabetes mellitus with macular edema resolved following treatment, unspecified eye

E13.311 Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 30: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

16 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E13.319 Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema

E13.3211 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye

E13.3212 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

E13.3213 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3219 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3291 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye

E13.3292 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye

E13.3293 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral

E13.3299 Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye

E13.3311 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye

E13.3312 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

E13.3313 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3319 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3391 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye

E13.3392 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye

E13.3393 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 31: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

17 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E13.3399 Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye

E13.3411 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

E13.3412 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

E13.3413 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral

E13.3419 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye

E13.3491 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye

E13.3492 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye

E13.3493 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral

E13.3499 Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye

E13.3511 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

E13.3512 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye

E13.3513 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

E13.3519 Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye

E13.3521Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye

E13.3522Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 32: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

18 of 20

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

E13.3523Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral

E13.3529Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye

E13.3531Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye

E13.3532Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye

E13.3533Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral

E13.3539Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye

E13.3541Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye

E13.3542Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye

E13.3543Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral

E13.3549Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye

E13.3551 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye

E13.3552 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye

E13.3553 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral

E13.3559 Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye

For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 33: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

Diabetic Retinopathy (Non Proliferative DR [NPDR] and Proliferative DR [PDR]) (cont)

TYPE CODE DESCRIPTION

E13.3591 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye

E13.3592 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

E13.3593 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral

E13.3599 Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye

E13.37X1 Other specified diabetes mellitus with macular edema resolved following treatment, right eye

E13.37X2 Other specified diabetes mellitus with macular edema resolved following treatment, left eye

E13.37X3 Other specified diabetes mellitus with macular edema resolved following treatment, bilateral

E13.37X9 Other specified diabetes mellitus with macular edema resolved following treatment, unspecified eye

Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 3 units)

Drug: NDC

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

10-digit 11-digit

50242-082-02 50242-0082-02 LUCENTIS 0.3-mg vial

50242-082-03 50242-0082-03 LUCENTIS 0.3-mg prefilled syringe

Administration procedures: CPT

67028 Intravitreal injection of a pharmacologic agent (separate procedure)

CPT modifier–LT Left eye modifier

–RT Right eye modifier

19 of 20For additional safety information, please see LUCENTIS full prescribing information.

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 34: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

20 of 20

LUCENTIS®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2019 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00001082(v1.0) 10/19

INDICATIONS & IMPORTANT SAFETY INFORMATION IndicationsLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

• Neovascular (wet) age-related macular degeneration (wAMD)

• Macular edema following retinal vein occlusion (RVO)

• Diabetic macular edema (DME)

• Diabetic retinopathy (DR)

• Myopic choroidal neovascularization (mCNV)

Important Safety InformationLUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONSIntravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.

for ® (ranibizumab injection)

Page 35: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

1 of 3

SAMPLE CODING

for ® (ranibizumab injection)

For additional safety information, please see LUCENTIS full prescribing information.

Wet-Age Related Macular Degeneration (wet AMD)

TYPE CODE DESCRIPTION

Diagnosis: ICD-10-CM

H35.3210 Exudative age-related macular degeneration, right eye, stage unspecified

H35.3211 Exudative age-related macular degeneration, right eye, with active choroidal neovascularization

H35.3212 Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

H35.3213 Exudative age-related macular degeneration, right eye, with inactive scar

H35.3220 Exudative age-related macular degeneration, left eye, stage unspecified

H35.3221 Exudative age-related macular degeneration, left eye, with active choroidal neovascularization

H35.3222 Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization

H35.3223 Exudative age-related macular degeneration, left eye, with inactive scar

H35.3230 Exudative age-related macular degeneration, bilateral, stage unspecified

H35.3231 Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization

H35.3232 Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization

H35.3233 Exudative age-related macular degeneration, bilateral, with inactive scar

H35.3290 Exudative age-related macular degeneration, unspecified eye, stage unspecified

H35.3291 Exudative age-related macular degeneration, unspecified eye, with active choroidal neovascularization

H35.3292 Exudative age-related macular degeneration, unspecified eye, with inactive choroidal neovascularization

H35.3293 Exudative age-related macular degeneration, unspecified eye, with inactive scar

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 36: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

for ® (ranibizumab injection)

2 of 3For additional safety information, please see LUCENTIS full prescribing information.

INDICATIONS & IMPORTANT SAFETY INFORMATION IndicationsLUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with:

• Neovascular (wet) age-related macular degeneration (wAMD)

• Macular edema following retinal vein occlusion (RVO)

• Diabetic macular edema (DME)

• Diabetic retinopathy (DR)

• Myopic choroidal neovascularization (mCNV)

Important Safety InformationLUCENTIS is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS. Hypersensitivity reactions may manifest as severe intraocular inflammation.

WARNINGS AND PRECAUTIONSIntravitreal injections, including those with LUCENTIS, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.

Increases in intraocular pressure have been noted both pre-injection and post-injection with LUCENTIS.

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LUCENTIS clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with LUCENTIS compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded.

Wet-Age Related Macular Degeneration (wet AMD) (cont)

TYPE CODE DESCRIPTION

Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units)

Drug: NDC

Note: Payer requirements regarding use of a 10-digit or 11-digit NDC may vary. Both formats are listed here for your reference.

10-digit 11-digit

50242-080-02 50242-0080-02 LUCENTIS 0.5-mg vial

50242-080-03 50242-0080-03 LUCENTIS 0.5-mg prefilled syringe

Administration procedures: CPT

67028 Intravitreal injection of a pharmacologic agent (separate procedure)

CPT modifier–LT Left eye modifier

–RT Right eye modifier

CPT=Current Procedural Terminology; HCPCS=Healthcare Common Procedure Coding System; ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification; LT=left; NDC=National Drug Code; RT=right.These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Many payers will not accept unspecified codes. If you use an unspecified code, please check with your payer.

Page 37: LUCENTIS Billing Codes - Genentech...Drug: HCPCS J2778 Injection, ranibizumab, 0.1 mg (bill 5 units) Drug: NDC Note: Payer requirements regarding use of a 10-digit or 11-digit NDC

3 of 3

LUCENTIS®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.

© 2019 Genentech USA, Inc. So. San Francisco, CA All rights reserved. M-US-00001082(v1.0) 10/19

Important Safety Information (cont)

WARNINGS AND PRECAUTIONS (cont)In the LUCENTIS Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough.

For additional safety information, please see LUCENTIS full prescribing information.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

For additional safety information, please see LUCENTIS full prescribing information.

for ® (ranibizumab injection)